Percutaneous transvenous mitral commissurotomy and transcatheter aortic valve replacement for rheumatic mitral and aortic stenosis


      The indications for transfemoral transcatheter aortic valve replacement (TAVR) have been expanding; however, treatment protocol for patients with severe aortic stenosis with other significant valve disease is still controversial. Furthermore, there are few randomized data to guide therapy in multivalvular disease. We describe a successful percutaneous transvenous mitral commissurotomy and TAVR simultaneously. A 3-year follow-up echocardiography showed preserved valve function.

      Learning objective

      A combination of percutaneous transvenous mitral commissurotomy and transcatheter aortic valve replacement for multivalvular disease with severe mitral stenosis and aortic stenosis may be a treatment option. For multivalvular disease, heart team decisions can be valuable for an optimal management strategy.


      TAVR (Transcatheter Aortic Valve Replacement), PTMC (Percutaneous Transvenous Mitral Commissurotomy), AS (Aortic Stenosis), MS (Mitral Stenosis)


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiology Cases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Joseph L.
        • Bashir M.
        • Xiang Q.
        • Yerokun B.A.
        • Matsouaka R.A.
        • Vemulapalli S.
        • et al.
        Prevalence and outcomes of mitral stenosis in patients undergoing transcatheter aortic valve replacement: findings from the Society of Thoracic Surgeons/American College of Cardiology transcatheter valve therapies registry.
        JACC Cardiovasc Interv. 2018; 11: 693-702
        • Unger P.
        • Lancellotti P.
        • de Cannière D.
        The clinical challenge of concomitant aortic and mitral valve stenosis.
        Acta Cardiol. 2016; 71: 3-6
        • Unger P.
        • Tribouilloy C.
        Aortic stenosis with other concomitant valvular disease: aortic regurgitation, mitral regurgitation, mitral stenosis, or tricuspid regurgitation.
        Cardiol Clin. 2020; 38: 33-46
        • Vassileva C.M.
        • Li S.
        • Thourani V.H.
        • Suri R.M.
        • et al.
        Outcome characteristics of multiple-valve surgery: comparison with single-valve procedures.
        Innovations (Phila). 2014; 9 (PMID: 24402042): 27-32
        • Sharma S.
        • Loya Y.S.
        • Desai D.M.
        • Pinto R.J.
        Percutaneous double-valve balloon valvotomy for multivalve stenosis: immediate results and intermediate-term follow-up.
        Am Heart J. 1997; 133: 64-70
        • Misuraca L.
        • Farah B.
        • Tchetche D.
        Concomitant transapical treatment of aortic stenosis and degenerated mitral bioprosthesis with two 29 mm Edwards sapien XT prostheses.
        J Invasive Cardiol. 2013; 25: 680-682
        • Baumgartner H.
        • Falk V.
        • Bax J.J.
        • De Bonis M.
        • Hamm C.
        • Holm P.J.
        • et al.
        ESC/EACTS guidelines for the management of valvular heart disease: the task force for the management of valvular heart disease of the european Society of Cardiology (ESC) and the european Association for Cardio-Thoracic Surgery (EACTS).
        Eur Heart J. 2017; 38: 2739-2791
        • Nishimura R.A.
        • Otto C.M.
        • Bonow R.O.
        • Carabello B.A.
        • Fleisher L.A.
        • Jneid H.
        • Mack M.J.
        • McLeod C.J.
        • O'Gara P.T.
        • Rigolin V.H.
        • Thompson A.
        • Erwin III, J.P.
        • Sundt III, T.M.
        2017 AHA/ACC focused update of the 2014 AHA /ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines..
        Circulation. 2017; 135: e1159-e1195